hydroxyurea

Novartis: EU approval for Jakavi® for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea

Jakavi® (ruxolitinib) approved by the European Commission for adult patients with polycythemia vera (PV) resistant to or intolerant of hydroxyurea…

9 years ago